Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that elevated STAT5 levels are linked to improved hair-inducing capabilities in human dermal papilla cells, and reducing STAT5 impairs hair follicle induction.

This study found that treating human dermal fibroblast cells with ginsenoside Rd increased the expression of mRNA associated with the dermal-epidermal junction, suggesting potential as an anti-aging cosmetic ingredient.

This study found that TGFbeta is a key pathway causing age-related loss of dermal fat's antimicrobial function, suggesting that targeting TGFBR might help restore skin defense against infections in older age.

This study found that the absence of Hes1 in hair follicles delays secondary hair germ activation and shortens the anagen phase, impacting HFSC self-renewal and long-term hair regeneration.

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

This review discusses the roles of αβ and γδ T cells in skin health and disease and reports no new clinical results; the authors highlight potential therapeutic developments.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This study found that H-Ras activation in aged mouse skin leads to increased dysplasia and progression to in situ squamous cell carcinoma, highlighting an age-linked connection between immune changes, senescence, and cancer risk.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

This review highlights recent insights into how IL-15 influences T cell responses and contributes to immunopathogenesis in various diseases, suggesting its crucial role in TCR-independent activation and potential in optimizing therapeutic strategies.

This study identified a novel G207E STING mutation associated with severe inflammatory symptoms and suggested that common polymorphisms in TMEM173 and IFIH1 may modify the phenotype in affected individuals.

This review discusses the effects of valproic acid on immune cell activation and gene expression, potentially influencing infection outcomes and suggesting its promise for autoimmune and hypersensitivity condition management.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.